DEFENSE-PFO: High Risk PFO Closure Reduces Combined Events and Stroke Risk

High risk patent foramen ovale closure PFO resulted in reduced stroke, vascular death and bleeding risk.

DEFENSE-PFO: el cierre FOP con ciertas características disminuye eventos combinados y strokeRecent reports have shown a favorable role of PFO in patients with cryptogenic stroke, though with some unclear results, which immediately raised the questions: Who are the optimal candidates for this procedure, and who will see no benefit?

 

This study focused on certain characteristics of PFO assessed by transesophageal ECG that could be risk predictors and tilt the scales for transcatheter PFO closure.


Read also: Stroke, Migraine and Patent Foramen Ovale Not Necessarily Temporary Associated.


The study included patients with cryptogenic stroke and high risk characteristics such as atrial septal aneurysm, septal hypermobility (phasic septal excursion into either atrium ≥10 mm), and PFO size (maximum separation of the septum primum from the septum secundum) ≥2 mm.

Primary endpoint was a composite of stroke, vascular death, or TIMI major bleeding during a 2 year follow-up.

 

It included 120 patients between 2011 and 2017 randomized to PFO closure vs. medical treatment alone. The three high risk characteristics of PFO were assessed by transesophageal ECG and resulted similar in both groups.


Read also: ACC 2018 | Echocardiographic Data Help Better Choose Patients for Patent Foramen Ovale Closure.


All PFO closure procedures were successful.

 

Primary end point was exclusively observed in the medication only group (6/60 patients; combined events rate at two years, 12.9% [p=0.013]; ischemic stroke rate at 2 years, 10.5% [p=0.023]).

 

In the medical treatment group, events included ischemic stroke (n=5), intercranial bleeding (n=1), TIMI major bleeding (n=2) and transient ischemic attack (n=1).


Read also: Closure of Patent Foramen Ovale for the Treatment of Migraine.


In the PFO closure group, complications included the development of atrial fibrillation (n=2), pericardial effusion (n=1) and pseudo aneurysm (n=1). There were no fatal complications.

 

Conclusion

Transcatheter patent foramen ovale closure in patients with a history of cryptogenic stroke and high risk characteristics assessed by transesophageal ECG, results in a significantly lower rate of stroke, vascular death and major bleeding, compared against patients undergoing medical treatment alone.

 

Original title: Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial.

Reference: Pil Hyung Lee et al. Journal of the American College of Cardiology (2018), online before print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Embolization of Left Atrial Appendage Closure Devices: Predictors, Prevention, and Management Strategies

Atrial fibrillation is associated with an increased risk of stroke and, in patients with contraindications to anticoagulation, percutaneous left atrial appendage closure represents an...

Coronary revascularization before TAVI: prior PCI or conservative management?

The coexistence of coronary artery disease (CAD) in patients with severe aortic stenosis undergoing TAVI is common, with a reported prevalence ranging from 30%...

Percutaneous Mechanical Aspiration versus Surgical Treatment of Tricuspid Valve Endocarditis

Tricuspid valve infective endocarditis (TVIE) accounts for approximately 5% to 10% of all cases of infective endocarditis. Surgical treatment remains the standard therapy in...

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...